ArticleScientific reports2025
Tanshinone IIA induces oxidative stress in trophoblast cells and enhances copper dependent death.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The clinical significance of miR-18a-3p in traumatic spinal cord injury and its functional role in mediating apoptosis, inflammation and oxidative stress.Journal of orthopaedic surgery and research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Oxidative stress occurs in trophoblast cells during the development of tubal pregnancy (TP), compared to normal pregnancy. It has been demonstrated that previous studies have shown that Tanshinone IIA (TSA) can increase reactive oxygen species (ROS) levels and exacerbate oxidative stress in tumor cells, while its effects on trophoblast cells or affects cuproptosis pathways remain unclear. We collected chorionic tissue from patients with normal intrauterine pregnancies (NP) or TP to detect the expression of related proteins. HTR-8/SVneo cells were cultured in vitro and treated with Elesclomol, CuCl2 and/or TSA, tetrathiomolybdate (TTM). The expressions of proteins such as DLAT, DLST, FDX1, Lipo-DLAT, Lipo-DLST, Bax, and Bcl-2 were measured. Mitochondrial membrane potential, cell apoptosis, and cell function were also assessed. The concentration of TSA added to HTR8-SVneo cells was 30 µM. The protein expression of DLAT, DLST, Lipo-DLAT, Lipo-DLST monomers, FDX1 and Bcl-2/ Bax was downregulated by the addition of Elesclomol and CuCl
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.